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Psychopharmaca belong to the most dangerous classes o f  drugs presently available 
The psychiatrist makes use o f psychopharmaca in extensive amounts but often without 
the basic knowledge which is needed in order to perform an adequate therapy. 
Psychopharmaca have been a great help in resocialization o f the mental patiënt. 
But it is also not surprising that many patients get into a deplorable condition be- 
cause o f psychopharmacotherapy.
Because of the creeping character o f the overdosage (excessive therapy) with 
psychopharmacologicai agents, iatrogenic diseases are often not discovered until it is 
too late for the patiënt. Especially elderly patients are apt to end their lives in an 
institution for the dement aged where they vegetate, as a result o f wrong treatment 
with psychopharmaca.
We might expect that psychoiogical research o f psychopharmaca in patients is 
done by using the necessary basic data of the drugs. However, this appears not to 
be the case. Basic data are either not known to the investigators or they do not exist. 
As a consequence many double-blind studies with psychopharmaca have very limited 
or no meaning at all.
(1 ) ACTION OF PSYCHOPHARMACOLOGICAL AGENTS ON THE 
CENTRAL NERVOUS SYSTEM
Psychopharmaca are ciassified, according to their main or required action, in neuro- 
leptics, tranquillizers, antidepressants, psychomotor stimulants, etc. Each drug has 
a variety o f behavioral effects which may be based on interaction with a particular 
type o f receptor in various areas o f the brain, interaction with different types o f re­
ceptors and also on the formation o f active metabolites which have a different 
spectrum o f action as parent compound.
Presented a t the Symposium on Pharmacopsychology on its Way?, organized by the Interdisciplinary 
Society o f Biological Psyehiatry, and held 15 Septem ber, 1972, in A m sterdam  (The N etherlands).
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Thus, neuroleptics act by blocking dopamine receptors in the brain, but these are 
localized in the neostriatum. The infundibular tract and the area postrema influence 
on motor function have endocrine effects and are anti-emetics.
The various amphetamines interact to a different extent on the dopamine system, 
the noradrenaline system and the 5-hydroxytryptamine system so that a large variety 
of central stimulant and other effects may be encountered. Diazepam is metabolized 
into desmethyldiazepam and oxazepam which have a spectrum o f action different 
from the parent drug.
The intensity o f  the behavioral effects induced by psychopharmacological agents 
and their metabolitès depends on the concentration o f such substances in the brain 
area where they find their locus of action. The concentration in discrete areas of the 
brain is related to the concentration in the blood plasma which in turn depends on 
the dose, the way o f administration, the rate o f absorption, distribution and elimi- 
nation. In other words the drug concentration in the brain will not be constant 
unless special precautions have been taken. Even if the concentration would remain 
constant, adaptation to the effects of the drug occurs so that the drug-induced change 
in behavior does not remain constant.
Furthermore, the behavioral pattern and the intensity o f the various behavioral 
items strongly depend on past experience, conditioning, culture, religion, the type o f  
psychological tests performed, etc. It may therefore be relatively easy to observe
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minim a in the curve show a t what tim e a fte r injection the indicated concentration is reached with the 
m inim um  dose capable o f  giving such a  level. The equi-effective dose curve representing EDso 
values o f  the anti-am phetam ine response a t various times. The equi-effective dose curve parallels 
the iso-concentration curve. (R eproduced from  Lewi et al. 16, w ith perm ission of the authors and
Arzneimittel Forschung.)
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Fig. 1. B: M ean plasma concentration curve o f  lysergide (LSD) on  a sem ilogarithm ic scale and the 
perform ance test scores both as function o f tim e after i.v. adm inistration o f  150 /<g. (D ata from
A ghajanian and Bing, / .)
drug-induced changes in human behavior, but it is difficult to evaluate dose-depen- 
dent studies.
Despite o f the inherent difficulties of drug-indüeed behaviora! studies, results have 
been obtained which ihdicate a reasonable correlation between brain content and 
neuroleptic action o f haloperidol (Fig. la) and between piasma concentrations and 
behaviora! changes induced by LSD (Fig. lb).
Since it is important to have some knowledge of the plasma concentration as a 
function of time after administration, basic information on pharmacokinetics is 
necessary in order to do fruitful research on drug-induced behavior.
(2) BASIC PHARMACOKLNETIC PARAMETERS
In pharmacotherapy one does not only use knowledge o f the action o f the drug on 
the body (pharmacodynamics), but also information regarding the action o f the body 
ori the drug (pharmacokinetics). If a drug is taken orally, absorption in the gastro- 
intestinal tract takes place followed by distribution over the various tissues of the 
body and elimination by means o f metabolism and excretion. In general, the elimi- 
nation is proportional to the quantity o f the drug in the body. This implies that after 
intravenous administration, at first elimination is rapid but progressively slows 
down when the drug content in the body decreases (see Fig. 2). The elimination 
either by metabolism or excretion may be considered as a clëarance process. This 
process is analogous to the situation in which a substance is cleared from a vessel 
by means o f a fresh water flow. The rate o f elimination and therefore the rate of 
decrease o f the concentration in the vessel is proportional to the fresh water flow 
and inversely proportional to the voiume o f  the vessel. Under such simplified con- 
ditions the body may be regarded as a vessel, a so-called single compartment, with a 
certain volume of distribution and a certain elimination clearance constant. Under 
such conditions the elimination rate may be characterized by the biological half-life.
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Fig. 2. A : Plasm a concenlration  decay curves o f dim ethylam phetam ine following öral adm inistration 
o f 35 mg in a solution to a hum an test subject. The experim ental data agree very well with the lines 
calculated for first order eiim ination o f the drug from  a single com partm ent. N ote a  rapid decrease 
initially, whiie as the concentralion drops the disappearance rate decreases. B: The plasma decay 
curve is straight in a sem ilogarithm ic plot. The biological half-life has been calculated from  this 
straight line. (Reproduced from  Vree (25) with permission o f the author.)
The biological half-life is then directly proportional to the volume of distribution and 
inversely proportional to the clearance constant.
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Various drugs which belong to the same pharmacological ciass may differ consider- 
ably with respect to the biological half-life and consequently in the volume o f distri-
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Fig. 3. Biphasic plasm a decay curves o f  diazepam  and thiopental. T here is a rapid decay initially 
followed by a slower exponential decay later on. This is m ore pronounced afte r i.v. adm inistration 
(thiopental) than  a fte r oral adm inistration. It is also evident th a t the  ra te  o f  absorp tion  will greatly 
affect the initial peak afte r oral adm inistration. The initial peak may be responsible for a  short 
effect a fte r a single dose, while the slow phase is im portant for accum ulation following chronic 
m edication. The curve for diazepam  has been calculated from  da ta  by Van der Kleijn et al., (14). 
The curve for thiopental has been calculated from  da ta  by Brodie et al., (7).
TABLE 1
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BIOLOG1CAL HALF-LIFE TIMES OF PSYCHOPHARMACOLOGICAL AGENTS
A. Psychomotor stimulant drugs and anorectic agents
ephedrine 6 hr ,




7 h r ! 
8-13 hr i Vree (25)
raetham phetam ine 8-15 hr 1
phenterm ine 10-12 hr
chlorpheriterm ine 2-3 d 1
B. Antidepressant drugs 
im ipram ine 3.5 hr \
desipram ine 36 hr [ 
20-60 hr )
H am m er et al. (11)
nortriptyline
C. Hypnotics
glutethim ide 10 hr B ütikofer (9)
m ethaqualone 2-3  hr M orris et al. (18)
butobarbital 40 hr Lam ers (15)
hexobarbital
cyclobarbital
4 h r / 
10-12 h r ) Breim er (4)
am obarbital 20-24 hr Balasubram aniam  et al. (2)
D. Tranquillizers and sedatives
m eprobam ate 10 hr (6-16 h) H ollister and Levy (12)
chlordiazepoxide 7-15 hr Schwartz et al. (22)
diazepam 36 hr Van der Kleijn et al. (14)
dem oxapam 15-50 hr Schwartz et al. (22)
barbital 56 hr Lous (17)
phenobarbital 50-70 hr Brilmayer and Loennecken (5)
e : Narcotic analgesics
m eperidine 5-6  hr Burns (8)
pentazocine 3-6  hr Beckett et al. (3)
m ethadone 6.5-7.5 h r Inturrisi and Verebely (13)




20 min / 
4 -6  h r  ( Rowland et al. (21)
paracetam ol 1.5-2.5 h r Nelson an d  M orioka (19)
phenacetine 1-1,5 hr Prescott et al. (20)
phenazon 10-12 hr Vesell and  Page (24)
am inophenazon 3 hr Brodie and Axelrod (6)
propyphenazon 2 h r Van G inneken (23a)
G. Antiparkinson agents
am antadine 9-15 hr Vree (25)
orphenadrine 10-12 hr Van G inneken (23a)
bution and the clearance constant. This is, for instance, the case for the hypnotic 
agents, the antidepressant drugs, the tranquillizers and other groups of psycho- 
pharmacological agents (see Table 1). It must be realized that for a number of psycho-
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pharmacologicai agents the bioiogical half-life is not known while for most drugs 
the volume o f distribution and the clearance constant is not known. In addition, for 
many pharmacologicai agents the body may not be regarded as a single compartment 
system. This implies that elimination does not proceed via a single exponential decay 
(see Fig. 3). This holds in general for psychopharmacoiogical agents. .<1 a ïy case, 
the concept o f  a clearance as well as the volume o f distribution also holds in the more 
complicated situation. The clearance constant can always be calculated from the 
plasma decay curve in which often more than one bioiogical half-life can be distin- 
guished.
(3 ) THE CONCENTRATION AND THE LOCUS OF ACTION IN RELATION 
TO THE PLASMA CONCENTRATION
Psychopharmacoiogical agents have the locus o f action in the central nervous system. 
In most cases more than one particular structure is involved. For instance, neuro- 
leptic drugs interact at least at the level of the neostriatum, the ventral hypothalamus 
and the midbrain chemöreceptor trigger zone. They do so by blocking dopamine 
receptors which are found to play a role in these structures. It is therefore evident 
that neuroleptic drugs may cause changes in motor performance, as for instance 
hypokinesia, endocrine effects, as for instance lactorrhoea, but also inhibit vomiting. 
All these effects are inherent in the dopamine receptor blocking action. Nevertheless, 
certain neuroleptic drugs may be selective by afffnity to some structures rather than 
to others. Following i.v. administration o f psychopharmacoiogical agents certain 
structures take up the drug more rapidly than others depending on the degree o f  
vascularization o f these structures and the physicochemical properties o f the drug. 
Therefore, differences in effect may occur following i.v. and oral administration. 
Since the drug is leaving the body by means o f a clearance process, in no instance 
can a true equilibrium be reached between the plasma concentration and the con­
centration in certain areas in the brain. If a drug, however, is slowly eliminated, a 
steadv state condition may occur some time after administration when absorption 
and distribution are complete. Drugs leaving the body very rapidly may not reach 
a steady state with respect to the diffusion between blood and brain. It is evident 
that following i.v. administration, depending on physical properties o f  the drug, 
initially the concentration in all areas o f the brain is low while the concentration of 
the plasma immediately after injection is high. Therefore the concentration in the 
highly vascularized areas increases rapidly provided that the drug passes the barrier 
rapidly enough and may be retained in the brain as a result o f the binding properties 
o f the drug to certain brain structures. The relation between the concentration in 
plasma and the concentration in the brain may therefore be very complicated. An 
unambiguous relationship, however, always occurs. It is obvious that one cannot 
expect to find the same relationships between the psychopharmacoiogical effect and 
the plasma concentration for the same drug in different situations (see Fig. 4). The way 
o f administration and the speed o f injection is o f importance. The relation between
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Fig. 4. Theoretica.1 curves representing drug concentration in plasma, and tissue rapidly equilibrating 
with plasma, the brain and the o th er tissues o f the body. In fact three  com partm ent kinetics are 
applied. The elim ination clearance is kept constant a t 86.8 m l/m in, while only the  clearance constant 
governing entry in the brain  is varied from  60 I/hr —»-2 1/hr. A: T he clearance p lasm a-brain is 
60 i/h r o r 1000 m l/m in. As a  result the brain concentration rises rapidly and rem ains higher than the 
plasm a concentration  and the fictive volume o f d istribution is 47 1. B: The p lasm a-brain  clearance 
is 10 1/hr o r 167 m l/m in. As a result plasm a and brain concentrations are practically equal and the 
fictive volume o f  d istribution  is 37 1. C: The p lasm a-brain  clearance is 2 1/hr o r 33 m l/m in. As a 
resu lt the  brain  concen tra tion  is always very low and the  fictive volume o f  d istribution is 35.5 1.
the same effective dose and the brain content o f the neuroieptic haloperidol is given. 
It may be concluded that the same effect corresponds well with an isoconcentration 
curve. In animals, the relation between plasma and brain concentration can be in-
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vestigated but in man one may only guess. In man, correlations can be found at the 
best between effects and the plasma decay curve. The picture is further complicated 
by the rate o f biotransformation o f the psychopharmacoiogical agent into one or 
more active metabolites which may have a similar or an entireiy different spectrum 
o f psychopharmacoiogical action.
(4) K1NETICS OF METABOL1SM OF DRUGS
lf  only one active metabolite is formed, it may be that the metabolite is cleared from 
the body more rapidly than the parent compound. One would expect then a lower 
concentration in the blood for the metabolites than for the parent drug (see Fig. 5). 
The plasma decay curve for metabolite and parent compound in the steady state 
conditions is o f equal shape. The plasma concentration o f the metabolites, however, 
may be relatively high if the volume o f distribution o f the metabolite is much smaller 
than that o f parent compound. Thus, from the relative concentrations o f metabolites 
and parent compounds not very much can be concluded unless additional information 
on volume and distribution is available.
plasma c o n c c n tn a tio n  -------------------------- -----------• p lasm a  c o n c e n tra t io n  ----------------------------- -i
( m g - / l  ■, l o g - s c a l e )  | ( m s f / l  > lo£'aoal«?)
Fig. 5. Pharm acokinetics o f m etabolism . Theory: A: The m etabolite is elim inated m ore rapidly 
than  the parent drug. B: The paren t d rug  disappears m ore rapidly than  the  m etabolite. Experim ental: 
C: Chlordiazepoxide is elim inated m ore rapidly than  one o f  its m etabolites desm ethylchlordiazepo- 
xide (subject 4). From  da ta  by Schwartz et al. (22), D: Flurazepam  is elim inated less rapidly than 
its m etabolites. F rom  data  by De Silva and Strojny (10).
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It is also possible that the metabolite leaves the body less rapidly than the parent 
compound; in such case the plasma decay curve o f  the metabolite is flatter than that 
of the parent compound. Then the half-life — if we may speak o f one half-life — of 
the metabolite is longer than that o f the parent compound, whereas in the previousl'' 
mentioned case both substances seemed to have equal half-lives. It is known, for 
instance, that diazepam is metabolized to a desmethyl compound and further metabo- 
lized to oxazepam. Both metabolites are biologically active although they have a 
different spectrum o f action than diazepam. The metabolites o f diazepam remain in 
the body much longer than the parent compound. This implies that initially after i.v. 
administration, the action is mainly due to the spectrum o f action o f diazepam. After 
oral administration the active metabolites may contribute to a large extent to the ac­
tion o f the drug. This will be more so after chronic administration when the meta­
bolites accumulate much more than the parent compound (see Fig. 5).
For many drugs such data are not available but one must realize the possibility, 
if  one studies the psychopharmacological effect certain time after administration.
The constantly changing concentration o f drug and its metabolites hardly allows 
a proper estimation o f the pharmacological activity. At what time after administra­
tion should a psyc.hological test be performed? At the plasma peak? But what is the 
contribution o f the metabolites? Depending on the rate o f elimination after the peak 
concentration, there is a more or less rapid decrease and, consequently, an ever 
changing brain concentration. If one knows the plasma concentration but does not 
know the biological half-life, what value can we attach to psychopharmacological 
data? Furthermore, in therapy the drugs are given chronically which may lead to a 
completely different picture.
(5) CHRONIC MEDICATION AND ACCUMULATION
In therapy with psychopharmaca a certain dosage regimen is established, for instance 
that the patiënt takes the drug every 8 hr. If in the dosage interval A t a substantial 
amount o f the drug remains in the body the next dose will be added on top, leading 
to accumulation (see Fig. 6). Since elimination is in general proportional to the 
plasma concentration, as a result o f accumulation the rate o f elimination increases 
so that accumulation slows down. Finally a plateau is reached. Then the input of 
drug equals the output and a steady state situation is reached not only with regard to 
the plasma but also with regard to the concentration in brain and other tissues.
It takes about 4 times the half-life to reach the plateau. E.g., desipramine with a 
half-life o f  approx. 36 hr will reach a plateau after almost a week. For bromide 
with a half-life o f  10 days, it will take more than a month to reach the plateau. Cessa- 
tion of administration may result in a slow plasma decay curve. This means that the 
drug remains in the body much longer than was expected from the plasma curve of  
a single dose (see Fig. 6b).
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Fig. 6. Pharm acokinetics o f accum uiation. A : T heory: A dose o f 1 m mole o f  a drug with a half-life 
o f 24 hr given oraily 3 dd (every 8 hr). W ithin 4 days a  plateau is reached. B\ Plasm a levels o f  dia- 
zepam  and m etabolite following chronic m edication o f  10 mg 3 dd fo r 15 days. In agreem ent with 
the long half-life the drug disappears slowly after cessation o f  therapy. This is m ore pronounced 
for the m etabolite which reaches a plateau after m ore than  one week. (R eproduced from  Van der 
Kieijn et al., 14, with permission o f the authors and the Acta 'Pharmacologica et Toxicologica.)
(6 ) CHRONIC ADMINISTRATION OF PSYCHOPHARMACA AND PLATEAU LEVELS
Repetitive administration o f drugs over sufficiently long periods o f time has the 
advantage that plateau levels are reached. This implies that the blood concentration 
is relatively constant at a fixed level provided that the elimination rate is not too 
rapid. Depending on the dosage interval and the pharmacokinetic parameters a cer­
tain degree o f oscillation occurs. If the dosage interval is short and the various half- 
lives are relatively long, the blood concentration in the plateau may be regarded as 
constant.
If the blood concentration can be kept constant also the drug concentration in the 
different areas o f  the brain will be constant (steady state). The same holds for the 
level o f possible metabolites formed from the parent psychopharmacological agent. 
It is then much easier to perfórm psychological tests. A disadvaritage o f chronic 
dosing is adaptation o f the brain systems. The action produced by the drug or meta­
bolite may be counteracted by adaptive mechanism. It is well known that a single 
dose o f 200 mg phenobarbital causes drowsiness in most patients. After chronic 
therapy with 30 mg 3 dd. a higher plasma concentration will be reached but drow­
siness is not apparent.
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(7) CONSTANT CONCENTRATIONS B Y  SUSTAINED RELEASE MEDICINES
Unless the time constants are larger than the dosage interval, substantial variation 
in the plateau concentration may occur. A better constancy may be acquired by in­
jection o f sustained release preparations. Fiom such preparations as for instance 
perphenazine enanthate, flupentixol decanoate or fluperazine enanthate constant 
plasma and tissue levels may be obtained. Consequently toxic side-effects are reduced 
to a minimum.
Another possibility is the development o f psychopharmaca that have strong 
affinity towards target tissues as for instance pimozide that binds to the neostriatum 
over prolonged periods o f time. These drugs are o f great help in therapy especially 
when the patients do not take the drugs regularly, as the case may be for chronic 
schizophrenics.
Such forms o f drug taking may also help the investigator in the study o f drug- 
induced behavior.
CONCLUSION
Superficial studies o f  drug-induced behavior can be done easily but it is very difficult 
to study adequate dose-dependent behavioral effects and to interpret their signifi- 
cance. The correct applications o f  pharmacokinetic knowledge is a prerequisite for 
such an understanding. The estimation o f blood levels o f parent drug and active 
metabolites is also necessary for such an understanding.
The use o f dosage regimens or drug administration measures which ensure constant 
steady state blood levels and thereby constant tissue levels facilitates the usefulness o f  
behavioral studies and limits the number o f blood level estimations.
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